Cargando…
Newer Anticoagulants for Non-Valvular Atrial Fibrillation
Non-valvular atrial fibrillation is a recognized risk factor for stroke and systemic embolism. It has been clearly established that warfarin reduces the risk of stroke and systemic embolism in persons with atrial fibrillation and additional risk factors for stroke. The use of warfarin, however, requ...
Autores principales: | Harburger, Joseph M., Aronow, Wilbert S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763648/ https://www.ncbi.nlm.nih.gov/pubmed/24281558 http://dx.doi.org/10.3390/ph5050469 |
Ejemplares similares
-
Association between direct-acting oral anticoagulants vs. warfarin with the risk of osteoporosis in patients with non-valvular atrial fibrillation
por: Akhtar, Tauseef, et al.
Publicado: (2020) -
Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014) -
Risk Stratification and Anticoagulation in Low-risk Non-valvular Atrial Fibrillation
por: Arya, Arash
Publicado: (2013) -
Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
por: Wu, Jia, et al.
Publicado: (2020) -
Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)